On Oct. 31, 2020, the U.S. Department of Health and Human Services and the U.S. Department of Defense jointly announced a $12.7 million contract with InBios International to expand domestic production capacity for two rapid point-of-care tests for SARS-CoV-2, the virus that causes COVID-19.

The first, called the SCoV-2 Ag Detect Kit, detects current infections by identifying antigens ﾖ genetic material ﾖ of the virus in a nose swab sample. The second test, called the SCoV-2 Detect IgM/IgG Kit, detects antibodies for the virus in a finger prick of blood, indicating whether the person had a previous COVID-19 infection.